Haloperidol-induced catalepsy: A model for screening antidepressants effective in treatment of depression with Parkinson's disease

Indian Journal of Experimental Biology

Volumn 35, Issue 12, 1997, Pages 1297-1301

  Khisti, R T ^a   Mandhane, S N ^a   Chopde, C T ^a  

^a RTM NAGPUR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; MAPROTILINE; MIANSERIN; NORTRIPTYLINE; PROTRIPTYLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PARKINSON DISEASE; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; CATALEPSY; DEPRESSIVE DISORDER; DRUG EVALUATION, PRECLINICAL; HALOPERIDOL; MALE; PARKINSON DISEASE; RATS;

EID: 0031463919     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Munkvad I, Pakkenberg H & Randrup A, Brain Behav Evol, 1 (1968) 89.
2. Hornykiewicz O, Br Med Bull, 29 (1973)172.
3. Narabayashi H, Kondo T, Yokochi F & Nagatsu T, in Advances in neurology, Vol.45, edited by Yahr MD & Bergmann KJ (Raven Press, New York) 1986, 593.
4. Balsara J J, Jadhav J H & Chandorkar A G, Psychopharmacology, 62 (1979) 67.
5. Hornykiewicz O, J Psychiat Res, 11 (1974) 249.
6. Bieliauskas L A & Glantz R H, J Clin Exp Neuropsychol, 11 (1989) 597.
7. Laitinen L, Acta Neurol Scand, 45 (1969) 109.
8. Muscettola G B, Giovanucci M, Montanini R & Morselli P, Rev Eur Etud Clin Biol, 17 (1972) 375.
9. Strang R R, Br Med J, 2 (1965) 33.
10. Chouinard G & Sultan S, Human Psychopharmacol, 7 (1992) 63.
11. Jansen Steur E N H, Neurology, 43 (1993) 211.
12. Keppel Hesselink J M, Human Psychopharmacol, 7 (1992) 411.
13. Porsolt R D, Le Pichon M & Jalfre M, Nature, 266 (1977) 730.
14. Seligman M E P & Beagley G, J Comp Physiol Psychol, 88 (1975) 534.
15. Katz R J, Neurosci Biobehav Rev, 5 (1981) 231.
16. Kulkarni S K, Arzi A & Kaul P N, Jap J Pharmacol, 30 (1980) 129.
17. Sanberg P R, Giordano M, Bunsey M D & Norman A B, Behav Neurosci, 102 (1988) 748.
18. Elliot P J, Close S P, Walsh A G, Hayes A G & Marriot A S, J Neural Transm (P D Sect), 2 (1990) 79.
19. Duvoisin R C, in The basal ganglia, edited by Yahr M D (Raven Press, New York) 1976, 293.
20. Briley M, Trend Pharmacol Sci, 14 (1993) 33.
21. Mavridis M, Degryse A D, Lategan A J, Marien M R & Colpaert F C, Neuroscience, 41 (1991) 507.
22. Narabayashi H, Bull Acad Med Bel, 139 (1984) 309.
23. Ungerstedt U, Acta Physiol Scand (Suppl), 367 (1971) 1.
24. Chopde C T, Hote M S, Mandhane S N & Muthal A V, J Neural Transm (Gen Sect), 102 (1995) 47.
25. Wadenberg M L, Neurosci Biobehav Rev, 20 (1996) 325.
26. Hicks P B, Life Sci, 47 (1990) 1609.
27. Silva S R, Futuro Neto H A & Pires J G P, Brazilian J Med Biol Res, 23 (1990) 869.
28. Hamon M, Fattaccini C M, Adrien J, Gallissot M C, Martin P & Gozlan H, J Pharmacol Exp Ther, 246 (1988) 745.
29. Dray A, Gonye T J, Oakley N R & Tanner T, Brain Res, 113 (1976) 45.
30. Kapur S & Remington G, Am J Psychiatry, 153 (1996) 466.
31. Ames D, Wirshing W C, Marder S R, Yuwiler A, Brammer G L, Midha K K & Van Putten T, Neuropsychopharmacology, 9 (1993) 116S.
32. Ketai R, Am J Psychiatry, 150 (1993) 836.
33. Clineschmidt B V, Vilataker I W, Faison E & Holmes R, Arch Int Pharmacodyn, 242 (1979) 59.
34. Elliot P J, Walsh P M, Close S P, Higgins G A & Hayes A G, Neuropharmacology, 29 (1990) 949.
35. Korsgaard S & Friis T, Psychopharmacology, 88 (1986) 109.